Reviewof Operations INTELLECTUAL PROPERTYPORTFOLIO The Group owns or exclusively licenses a broad intellectual property (IP) portfolio of granted patents, patent applications, trade secrets and trademarks protecting its core technologies, products, processes and brands. The Group had 42 granted patents, 14 patents pending and 2 international (PCT) applications as at 22 July 2022, covering its SubB2M, Molecular NET, BARD1, and hTERT technologies and products across key jurisdictions including the United States, Europe, Asia, and Australia. The Group also owns registered trademarks for INOVIQ®, EXO-NET® and Acuris®. During FY22, the following patents were issued: – On 12 November 2021, INOVIQ announced that US Patent No 11137402 titled ‘Lung Cancer Diagnosis’ was issued by the United States Patent and Trademark Office. – On 24 December 2021, INOVIQ announced that Chinese Patent ZL 201480071075.7 titled ‘Lung Cancer Diagnosis’ was issued by the Chinese Patent Office. – On 17 January 2021, INOVIQ announced that US Patent 11,193,944 titled ‘Kits for detecting breast or ovarian cancer in a body fluid sample and use thereof’ was issued by the United States Patent and Trademark Office. – On 23 February 2022, INOVIQ announced that Brazilian Patent 112013003506 titled ‘BARD1 isoforms in lung and colorectal cancer and use thereof’ was issued by the National Institute of Industrial Property (INPI). – On 3 May 2022, INOVIQ announced that Australian Patent No 2017358401 titled ‘Subtilase cytotoxin B subunit mutant’ was issued by IP Australia to Griffith University and the University of Adelaide. INOVIQ Ltd holds the exclusive worldwide rights to the SubB2M intellectual property for diagnostic applications. – Post year-end, on 1 July 2022, INOVIQ announced that US Patent No 11,371,033 titled ‘Subtilase cytotoxin B subunit mutant’ was issued by the United States Patent and Trademark Office. – On 22 July 2022, INOVIQ announced that US Patent No 11,391,738 titled ‘Method of detecting cancer’ was issued by the United States Patent and Trademark Office to Sienna Cancer Diagnostic Ltd, a subsidiary of INOVIQ. INOVIQ Patent Status Summary Strong patent portfolio • Broad patent portfolio protecting IIQ’s core biomarker isolationand detection technologies and products • IP owned or exclusively licensed • 42 granted patents, 14 pending and 2 international (PCT) applications (at 22/7/22) • Protection across key jurisdictions (including US, Europe, Asia & Australia) • Registered trademarks for INOVIQ® and EXONET® Patent Family Title Granted Pending Expiry SubB2M PCT/AU2017/051230 (WO 2018/085888) Subtilase cytotoxin B subunit mutant AU, US BR, CA, CN, EP, IN, JP, KR, US (cont) 2037 PCT/AU2022/050470 Methods of analysing a sample 2042 BARD1 PCT/FR01/02731 (WO/2002/018536) Truncated BARD1 protein, and its diagnostic and therapeutic uses US 2024 PCT/IB2011/053635 (WO/2012/023112) BARD1 isoforms in lung and colorectal cancer and use thereof AU, BR, CA, CN, CN(div) EP, HK, IL, JP, JP(div), SG, US, US (cont) 2031 PCT/IB2011/054194 (WO/2012/038932) Kits for detecting breast or ovarian cancer in a body fluid sample and use thereof EP, US, US (cont) 2031 PCT/EP2014/073834 (WO/2015/067666) Lung Cancer Diagnosis AU, CN, IL, JP, SG, KR, US CA, EP, HK 2034 EP14002398.7 Non-coding RNA as diagnostic marker and treatment target US 2035 hTERT PCT/AU2015/050060 (WO2015/120523) Method of resolving inconclusive cytology to detect cancer AU, CN, EP, IL, JP, US, US(cont) 2035 PCT/AU2016/050764 (WO2017/027928) Method of detecting cancer in morphologically normal cells JP US 2036 Molecular NETs PCT/US2010/058086 (WO2011/066449) Devices for detection of analytes CN, US(cont1), US(cont2), US(cont3) US(cont5) 2030 PCT/US2013/049779 (WO2014/011673) Molecular Nets EP 2033 PCT/US2014/029823 (WO2014/153262) Molecular nets on solid phases AU, CN CA 2034 PCT/AU2022/050428 Methods relating to tumour-derived extracellular vesicles 2042 cont = continuation; div = divisional 25 | 9 AUGUST 2022 18 INOVIQ Limited
RkJQdWJsaXNoZXIy MjE2NDg3